ABSTRACT
The efficacy of two commercially available throat lozenges (test preparation with lysozyme, papain and bacitracin as active ingredients, comparative preparation with a disinfectant only) has been tested under conditions of a randomized clinical study. Two groups of 50 patients each with the indications pharyngitis and/or tonsillitis, acute or subacute, have been compared under the conditions of an ENT-practice. The efficacy of the test preparation was established by the general amelioration evaluated by physician and patient and the symptoms reddening, swelling and coating of the throat, pain on swallowing and hoarseness, swelling and pain of lymph nodes. It is supposed that this superiority is due to the enzyme lysozyme and papain in the test preparation.
Subject(s)
Anti-Infective Agents, Local/therapeutic use , Bacitracin/therapeutic use , Muramidase/therapeutic use , Papain/therapeutic use , Pharyngitis/drug therapy , Adult , Drug Therapy, Combination , Female , Hoarseness/drug therapy , Humans , Male , Tonsillitis/drug therapyABSTRACT
In a controlled clinical trial Frubienzym (throat lozenges with 5 mg lysozyme, 2 mg papaine and 200 I.U. bacitracin) or placebo have been given to 100 patients with pharyngitis and/or tonsillitis for 4 days. Under treatment with Frubienzym reddening, swelling, matter and mucus in the throat, coughing, swelling and pain of lymphatic ganglions and pain of swallowing vanished more quickly than under placebo. The differences were significant (p less than 0,05, p less than 0,001 or even p less than 0,001; U-test of Wilcoxon, Man and Whitney). There were no side effects which could be attributed to Frubienzym.
